ARHGEF4: A Potential Drug Target and Biomarker (G50649)

Target Name: ARHGEF4

NCBI ID: G50649

ARHGEF4

ARHGEF4: A Potential Drug Target and Biomarker

Introduction

Autosomal recessive genetic disorders are a group of conditions that are caused by mutations in genes that are essential for the development and function of the body. These disorders can be severe and life-threatening, and there is currently no cure. However, in some cases , advances in medical research may identify drug targets or biomarkers that can help treat these conditions. The article will focus on ARHGEF4, a gene that has been identified as a potential drug target and biomarker for some autosomal recessive genetic disorders.

ARHGEF4: The ARHGEF4 gene

ARHGEF4 is a gene that encodes a protein known as ARHGEF4. This protein plays a crucial role in the development and function of the blood vessels, which are responsible for delivering oxygen and nutrients to the body's cells. ARHGEF4 is a member of a family of genes called the ARG/GGF-associated receptor gene (ARG/GGF-AR), which is characterized by a specific translocation event in the genomic sequence.

The ARHGEF4 gene was first identified in 2002, and it has been extensively studied since then. Studies have shown that ARHGEF4 is involved in various physiological processes in the body, including cell signaling, angiogenesis, and inflammation. In addition, ARHGEF4 has been implicated in the development of several autosomal recessive genetic disorders, including cardiovascular disease, neurodegenerative diseases, and autoimmune diseases.

ARHGEF4 as a drug target

Drug targets are proteins that are targeted by drugs in order to inhibit their function and treat diseases. In the case of ARHGEF4, its potential as a drug target is due to its involvement in various physiological processes that are important for the development and function of the body.

One of the key functions of ARHGEF4 is its role in cell signaling. ARHGEF4 is a member of the G protein-coupled receptor (GPCR) family, which is a broad class of transmembrane proteins that play a crucial role in cellular signaling. GPCR signaling pathways are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. By modulating the activity of these pathways, ARHGEF4 can be targeted by drugs that affect its function.

ARHGEF4 is also involved in the regulation of angiogenesis, the process by which new blood vessels are formed in the body. This is important for delivering oxygen and nutrients to the body's cells, and is also involved in the development and function of the blood vessels. By targeting ARHGEF4, drugs can be developed that treat conditions such as heart disease, neurodegenerative diseases, and autoimmune diseases.

In addition to its role in cell signaling and angiogenesis, ARHGEF4 is also involved in the regulation of inflammation. This is important for the immune system's response to foreign substances, including bacteria, viruses, and cancer cells. By modulating the activity of inflammation-related pathways, ARHGEF4 can be targeted by drugs that treat autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis.

ARHGEF4 as a biomarker

In addition to its potential as a drug target, ARHGEF4 has also been identified as a potential biomarker for some autosomal recessive genetic disorders. These disorders are characterized by a range of symptoms and disabilities, and can be severe and life-threatening. However, advances in genetic testing and research have identified new treatments for these disorders, and ARHGEF4 is

Protein Name: Rho Guanine Nucleotide Exchange Factor 4

Functions: Acts as guanine nucleotide exchange factor (GEF) for RHOA, RAC1 and CDC42 GTPases. Binding of APC may activate RAC1 GEF activity. The APC-ARHGEF4 complex seems to be involved in cell migration as well as in E-cadherin-mediated cell-cell adhesion. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Involved in tumor angiogenesis and may play a role in intestinal adenoma formation and tumor progression

The "ARHGEF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets